Figure 5

Isoliquiritigenin reduces Akt-mTOR signaling pathway activity.

(a) Immunoblotting of phosphorylation P70 S6 kinase and total P70 S6 kinase in CD4⁺ T cells under Treg-inducing conditions and treated with isoliquiritigenin or naringenin for indicated times. (b) Quantitative PCR analyses of gene expressions in CD4⁺ T cells under Treg-inducing conditions treated with isoliquiritigenin or naringenin. (c) Immunoblot of phosphorylation Akt and Erk in CD4⁺ T cells under Treg-inducing conditions and treated with isoliquiritigenin or naringenin for indicated times. (d) Immunoblotting of phosphorylation Akt and Erk in CD4⁺ T cells under Treg-inducing conditions and treated with licorice or Gly1 fraction for indicated times. (e) Quantitative PCR analyses of Cyp1a expression in CD4⁺ T cells treated with licorice, Gly1 fraction, isoliquiritigenin or naringenin. The immunoblot in (a,c,d) were run under the same experimental conditions. Cropped blots were shown in (a,c,d) and the full-length blots were presented in Supplementary Figure 10. Results are expressed as means ± SEM and are representative of more than three experiments. *P < 0.05, **P < 0.01 and ***P < 0.001, as determined by one-way ANOVA followed by Bonferroni’s test (b,e).